Table 3.

Safety summary (randomized population)

	DM-DYSLIPIDEMIA		DM-INSULIN
	Alirocumab (n = 95)	UC (n = 47)	Alirocumab (n = 118)	Placebo (n = 57)
TEAEs occurring in ≥ 2% of individuals by preferred term, n (%)
Urinary tract infection	5 (5.3)	2 (4.3)	3 (2.5)	4 (7.0)
Diarrhea	5 (5.3)	3 (6.4)	3 (2.5)	3 (5.3)
Hypertension	3 (3.2)	1 (2.1)	5 (4.2)	3 (5.3)
Influenza	3 (3.2)	3 (6.4)	4 (3.4)	1 (1.8)
Musculoskeletal pain	4 (4.2)	1 (2.1)	3 (2.5)	2 (3.5)
Back pain	2 (2.1)	2 (4.3)	4 (3.4)	0
Dizziness	3 (3.2)	1 (2.1)	3 (2.5)	2 (3.5)
Fatigue	2 (2.1)	2 (4.3)	3 (2.5)	1 (1.8)
Cataract	1 (1.1)	1 (2.1)	4 (3.4)	0
Myalgia	2 (2.1)	1 (2.1)	3 (2.5)	0
Nausea	2 (2.1)	1 (2.1)	2 (1.7)	2 (3.5)
Pain in extremity	2 (2.1)	2 (4.3)	2 (1.7)	1 (1.8)
Bronchitis	0	2 (4.3)	3 (2.5)	1 (1.8)